Intra-Cellular Therapies Inc. (NASDAQ:ITCI) shares saw unusually-strong trading volume on Friday . Approximately 380,143 shares were traded during mid-day trading, a decline of 33% from the previous session’s volume of 569,388 shares.The stock last traded at $21.61 and had previously closed at $22.10.

A number of research analysts have recently issued reports on ITCI shares. Cantor Fitzgerald set a $29.00 price target on shares of Intra-Cellular Therapies and gave the stock a “buy” rating in a research report on Thursday, May 11th. Leerink Swann upgraded shares of Intra-Cellular Therapies from a “market perform” rating to an “outperform” rating in a research report on Wednesday, August 23rd. ValuEngine downgraded shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Tuesday, May 16th. Finally, BidaskClub downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $25.11.

The company’s market cap is $928.84 million. The stock’s 50-day moving average price is $13.42 and its 200-day moving average price is $12.73.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.33. Intra-Cellular Therapies had a negative return on equity of 27.92% and a negative net margin of 32,834.94%. The company had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.03 million. During the same quarter last year, the firm posted ($0.71) earnings per share. The firm’s revenue was down 52.2% on a year-over-year basis. Analysts expect that Intra-Cellular Therapies Inc. will post ($2.36) earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the business. FMR LLC lifted its position in Intra-Cellular Therapies by 0.3% during the first quarter. FMR LLC now owns 6,511,541 shares of the biopharmaceutical company’s stock valued at $105,813,000 after buying an additional 21,305 shares during the period. Vanguard Group Inc. lifted its position in Intra-Cellular Therapies by 7.3% during the first quarter. Vanguard Group Inc. now owns 2,741,887 shares of the biopharmaceutical company’s stock valued at $44,556,000 after buying an additional 186,165 shares during the period. BB Biotech AG lifted its position in Intra-Cellular Therapies by 11.7% during the second quarter. BB Biotech AG now owns 2,150,000 shares of the biopharmaceutical company’s stock valued at $26,703,000 after buying an additional 225,000 shares during the period. Wasatch Advisors Inc. lifted its position in Intra-Cellular Therapies by 65.1% during the second quarter. Wasatch Advisors Inc. now owns 1,659,513 shares of the biopharmaceutical company’s stock valued at $20,611,000 after buying an additional 654,400 shares during the period. Finally, State Street Corp lifted its position in Intra-Cellular Therapies by 10.4% during the second quarter. State Street Corp now owns 1,004,360 shares of the biopharmaceutical company’s stock valued at $12,474,000 after buying an additional 94,763 shares during the period. 71.79% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This story was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/09/08/intra-cellular-therapies-inc-itci-sees-strong-trading-volume-3.html.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.